课题基金 / 基金详情

Pathogenesis And Treatment Of Neurodegenerative Disease

Pathogenesis And Treatment Of Neurodegenerative Disease
神经退行性疾病的发病机制和治疗
批准号:
7322995
负责人:
MARK A HALLETT
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

MARK A HALLETT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Improving the translation of recent findings from basic laboratory research to better therapies for neurologic disease constitutes a major challenge for the neurosciences as well as a critical goal for Branch research. ETB recent contributions to the development of several treatments for Parkinson?s disease (PD) illustrate approaches to some of the relevant issues. Building on our previous findings in rodent and primate models of PD, our clinical studies have discovered the potential therapeutic benefit of various drugs, including our recently completed trials involving non-dopaminergic treatments that target selected striatal transmitter receptors, such as adenosine A2a, serotonin 5HT1A and alpha-2 adrenergic autoreceptors. We have demonstrated that drugs of these types can modulate striatal dopaminergic function and may be useful as adjuvant in the treatment of this disorder. These works exemplify a strategy for successfully bridging a novel approach to PD therapy from an evolving research concept to pivotal clinical trials. During the past year we conducted additional translational proof-of principle studies aimed at advancing the treatment of motor complications in PD. These trials evaluated the effects of serotonin 5HT2 A/C blockade and continuous transdermal dopaminergic stimulation on parkinsonian symptoms and on motor complications in advanced PD, including motor fluctuations and levodopa-induced dyskinesias. In addition to these investigations on PD, our branch also completed last year two research projects on the pathophysiology of the restless legs syndrome (RLS). In the first study, the role of dopaminergic mechanisms in spinal flexor reflex circuitry was investigated in a double blind randomized trial of ropinirole versus placebo in patients with RLS. The second study evaluated the potential contribution of sensorimotor gating abnormalities in the pathophysiology of this condition. These studies are important to understand the possible mechanisms underlying this frequent neurological disorder.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
帕金森病的纹状体分子机制和运动功能障碍。
DOI: --
发表时间: 2001
期刊: Advances in neurology
影响因子: --
作者: [Chase,TN, Konitsiotis,S, Oh,JD]
通讯作者: Oh,JD
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
寻求治疗性 A2A 拮抗剂的进展:腺苷 A2A 受体选择性拮抗剂 KW6002:针对帕金森病的新型非多巴胺能疗法的研究和开发。
DOI: 10.1212/01.wnl.0000095219.22086.31
发表时间: 2003
期刊: Neurology
影响因子: 9.9
作者: [Kase,Hiroshi, Aoyama,S, Ichimura,M, Ikeda,K, Ishii,A, Kanda,T, Koga,K, Koike,N, Kurokawa,M, Kuwana,Y, Mori,A, Nakamura,J, Nonaka,H, Ochi,M, Saki,M, Shimada,J, Shindou,T, Shiozaki,S, Suzuki,F, Takeda,M, Yanagawa,K, Richardson,PJ, Jen]
通讯作者: Jen
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
喹硫平可减轻啮齿动物和灵长类帕金森病模型中左旋多巴引起的运动并发症。
DOI: 10.1006/exnr.2002.8009
发表时间: 2002
期刊: Experimental neurology
影响因子: 5.3
作者: [Oh,JustinD, Bibbiani,Francesco, Chase,ThomasN]
通讯作者: Chase,ThomasN
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
亨廷顿病:一项使用 NMDA 拮抗剂金刚烷胺的随机对照试验。
DOI: 10.1212/wnl.59.5.694
发表时间: 2002
期刊: Neurology
影响因子: 9.9
作者: [VerhagenMetman,L, Morris,MJ, Farmer,C, Gillespie,M, Mosby,K, Wuu,J, Chase,TN]
通讯作者: Chase,TN
10
    PHYSIOLOGICAL ANALYSIS OF VOLUNTARY MOVEMENT
    PHYSIOLOGICAL ANALYSIS OF INVOLUNTARY MOVEMENTS
    Physiological Analysis Of Involuntary Movements
    Pathogenesis And Treatment Of Neurodegenerative Disease
    海外基金